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Abstract 
Purpose: To investigate the anti-asthmatic effects of the flavonoid rutin in an ovalbumin (OVA)-induced 
asthmatic mouse model. 
Methods: Asthma was induced by OVA induction. Effects of rutin (25–100 mg/kg BW) on interleukins 
(IL)-4, IL-5, and IL-13 and interferon (IFN)-γ in bronchoalveolar lavage fluid (BALF) and serum OVA-
specific IgE levels were assessed by enzyme linked immunosorbent assay (ELISA). Airway 
hyperresponsiveness (AHR) was measured by determining lung compliance and airway resistance. 
Expression levels of p-I-κBα, p-NF-κB p65, TNF-α, and Foxp3 were also assessed. The CD4+ CD25+ 
Foxp3+ T regulatory cell population was determined by flow cytometry. 
Results: Rutin significantly (p < 0.05) decreased Th2 cytokines (IL-4, IL-5, IL-13), whereas it enhanced 
IFN-γ levels in BALF. Decreased OVA-specific serum IgE was also observed with improved lung 
histology. Rutin was effective in reducing AHR and regulating the expression levels of p-I-κBα, p-NF-κB 
p65, and TNF α, and also increased the CD4+ CD25+ Foxp3+ Treg cell population and Foxp3 mRNA 
and protein levels. 
Conclusion: Rutin effectively suppresses OVA-induced asthma and improves airway function by 
suppressing inflammatory mediators and inflammatory cell infiltration. 
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Allergic asthma is a chronic airway disorder 
characterised by airway inflammation, airway 
hyperresponsiveness (AHR), and mucus 
hypersecretion [1]. The prevalence of asthma is 
increasing globally, especially in children [2]. An 
imbalance in the equilibrium between T helper 
cell type 1 (Th1) and T helper type 2 (Th2) 
immune responses appears to be the underlying 
mechanism that leads to the asthmatic 
inflammatory response, with an increased Th2 
response [3]. Th2 cell-derived cytokines (IL-4, IL-
5, IL-13) play key roles in the pathogenesis of 
asthma and have been implicated in AHR 
development, eosinophil accumulation, mucus 
hypersecretion, and lung remodelling [4]. 
 
It has also been demonstrated that NF-κB plays 
an important role in the pathogenesis of asthma 
[5]. NF-κB has been shown to be involved in the 
production of Th2 cytokines and in the 
recruitment of inflammatory cells [6], making NF-
κB a potential molecular target in therapeutic 
strategies for asthma. Corticosteroids have long 
been used as the main therapeutic drug in 
asthma [7]. However, such treatments do not 
‘cure’ the disease or even alter disease 
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progression; indeed, the symptoms return soon 
after treatment termination and the prolonged 
use of corticosteroids causes systemic and local 
side effects [8].  
 
The use of natural plant products as alternative 
medicines in the treatment of various disease 
conditions has increased [9]. The flavonoids are 
a family of common phenolic plant pigments that 
possess anti-carcinogenic and anti-oxidant 
properties. Studies have also shown profound 
immunoregulatory activities [10]. Rutin, a 
flavonoid found especially in citrus fruits, such as 
lemon, grapefruit, lime, and orange, has anti-
oxidant and anti-inflammatory activities [11]. 
Here, we investigated whether rutin could offer 
protection in asthmatic mice, via downregulation 





Chemicals and antibodies 
 
Antibodies against p-NF-κB p65, p-Iκ-Bα, TNF-α, 
Foxp3, and β-actin were from Cell Signaling 
Technology (Beverly, MA, USA). Rutin and 
ovalbumin (OVA) were from Sigma-Aldrich (St. 
Louis MO, USA). FITC-labelled anti-rat CD4, 
APC-labelled anti-rat CD25, and PE-labelled 
anti-rat Foxp3 were from eBioscience Co. (San 
Diego, CA, USA). All other chemicals and 





Female BALB/c mice (18–22 g) were obtained 
from the Experimental Animal Centre of China 
Pharmaceutical University (Nanjing, China). All 
animals were housed in a sterile room (24 ± 1 
°C, 40–60 % humidity) and were supplied with 
water and food ad libitum. The mice were 
acclimatised to the conditions for 1 week prior to 
experimentation. All experiments were performed 
in compliance with the Guidelines For the Care 
and Use of Laboratory Animals [12] and the 
study was approved by the Ethics Committee of 
Jining Medical University (Approval reference 
number:YXSA12443). 
 
Ovalbumin sensitisation and challenge 
 
Mice were sensitised and challenged with OVA 
as described previously [13] with minor 
modifications. OVA at 500 µg/mL in PBS was 
mixed with equal volumes of 10 % (w/v) aqueous 
aluminium potassium sulphate (alum; Sigma) 
and incubated at room temperature for about 1 h 
at pH 6.5 and centrifuged (750g, 5 min). The 
OVA/alum pellet was suspended to its original 
volume in distilled water. The animals were given 
100 µg of OVA (0.2 mL of 500 μg/mL solution in 
normal saline) intraperitoneally (i.p.) on the first 
day. Mice were exposed to 250 μg OVA (100 µL 
of a 2.5 mg/mL solution) on day 8, and on days 
15, 18, and 21, mice were challenged with 125 
μg OVA (50 µL of 2.5 mg/mL solution) 
intranasally (i.n.), as described previously [13]. 
Mice were exposed to ketamine anaesthesia (i.p. 
injection of 0.2 mL of a mixture of ketamine, 0.44 
mg/mL, and xylazine, 6.3 mg/mL, in normal 
saline) prior to OVA challenge. In the treatment 
group, rutin was administered at 25, 50, 
100 mg/kg bodyweight (BW) orally every day 
from day 1 to day 21. On the days of OVA 
challenge, the mice received rutin 60 min before 
injections. A separate group of mice received 
dexamethasone (Dex; 2 mg/kg) i.p. 1 h before 
OVA injections. Dex served as a positive control. 
The normal control mice received no injections or 
rutin. 
 
Collection and analysis of bronchoalveolar 
lavage fluid (BALF) 
 
The mice were sacrificed after 24 h following the 
last OVA challenge, by pentobarbital overdose, 
and a tracheotomy was performed. Ice-cold PBS 
(0.5 mL) was infused into a lung and BALF was 
obtained by three successive aspirations (total 
volume 1.5 mL) via tracheal cannulation [14]. 
The collected BALF was then centrifuged (250 g, 
5 min, 4 °C) and the supernatant was collected 
and stored at -70 °C. The supernatant was used 
for cytokine assays. The cell pellets were 
resuspended in PBS and differential cell counts 
were determined by staining with the Wright-
Giemsa staining method. 
 
BALF levels of IL-4, IL-5, IL-13 and IFN-γ were 
determined using ELISA. Kits were purchased 
from R&D Systems (Minneapolis, MN, USA). 
 
Determination of OVA-specific IgE 
 
Whole blood was collected and centrifuged (3, 
000 rpm, 10 min, 4 °C) and the serum was 
separated and stored at -80 °C. OVA-specific 
serum IgE levels were determined using the 
Legend Max mouse OVA-specific IgE ELISA kit 
(BioLegend, San Diego, CA, USA) according to 
the manufacturer’s protocol. 
 
Measurement of airway hyperresponsiveness 
 
Change in airway function was assessed as 
AHR, following challenge with aerosolised 
methacholine via the airway. AHR was 
determined using Buxco’s modular and invasive 
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system (Buxco Electronics Inc., Wilmington, NC, 
USA). Changes in lung compliance (Cdyn) and 
airway resistance (RI) in response to increasing 
concentrations of methacholine were recorded 
directly, as described previously [15]. Briefly, the 
rats were tracheotomised and cannulated and 
placed in a whole body plethysmograph chamber 
connected to the ventilator. The rats were given 
various concentrations of methacholine (3.125, 
6.25, 12.5, 25 mg/mL) via a jet nebuliser into the 
head chamber. The values are expressed as 
percentage of the respective basal values in 




Lung tissues were collected and fixed in 10 % 
formalin, and embedded in paraffin wax; 5-μm 
sections were cut and stained with haematoxylin 
and eosin (H&E). For examination of mucus 
production, periodic acid-fluorescence Schiff 
stain (PAFS) was used. The mucin granules emit 
red fluorescence at excitation wavelengths of 
380–580 nm and were observed at 600–650 nm 
using a Leica TCS SP5 confocal microscope 
(Leica Microsystems, Richmond, IL, USA) as 
described previously [16]. The inflammatory 
scores and expression levels of mucus-positive 
cells were calculated as described previously 
[17]. 
 
Flow cytometric analysis for CD4+ CD25+ 
Foxp3+ expression 
 
Cells from the BALF were analysed for CD4+ 
CD25+ Foxp3+ expression. Briefly, prepared cells 
(1 × 106) were washed by centrifugation in flow 
cytometry staining buffer. For Treg analysis, cells 
were incubated with FITC-labelled anti-CD4 and 
APC-labelled anti-CD25 antibodies in staining 
buffer and incubated for 30 min at 4 °C. 
Following surface staining, the cells were fixed, 
permeabilised, and subsequently stained with 
anti-rat Foxp3 and finally resuspended in staining 
buffer and subjected to analysis by flow 
cytometry (FACSCalibur instrument with 
CellQuest software; BD Biosciences, Mountain 
View, CA, USA). 
 
Quantitative real-time (RT)-PCR 
 
The lung tissues of each group were 
homogenised in 1 mL of TRIzol (Invitrogen) using 
a glass homogeniser. Total RNA was isolated 
according to the manufacturer’s protocol. RNA 
specific for Foxp3 was amplified using specific 
primers: Foxp3, 5’-CCC TCA AAG TTA CAA 
TCCTG-3’ (forward) and 5’-GGG TTA GTG GCA 
AGT GAT A-3’ (reverse), and GAPDH, 5’-GGG 
GAG CCA AAA GGG TCA TC-3’ (forward) and 
5’-GAC GCC TGC TTC ACC ACC TTC TTG-3’ 
(reverse). Amplification was performed under the 
following conditions: initial denaturation at 94°C 
for 10 min followed by 40 cycles of 94 °C for 20 s 
and annealing at 53 °C for 25 s, and a final 
extension at 72 °C for 30 s in a Line-Gene FQD-
33A instrument (Bioer Inc., Hangzhou, China). 
 
Western blot analysis 
 
Following homogenisation of the lung tissue, the 
cells were subjected to lysis on incubation with 
0.5 mL ice-cold whole-cell lysate buffer (0.5 M 
EDTA, 5 M NaCl, 10 % Nonidet P-40, 0.1 M 
phenylmethylsulphonyl fluoride, 0.1 M EGTA, 1 
M sodium fluoride, 1 M HEPES, 0.2 M sodium 
orthovanadate, 2 µg/mL aprotinin and 2 µg/mL 
leupeptin) on ice for 30 min. Protein 
concentrations were determined by a Bradford 
assay using a kit from Bio-Rad (Bio-Rad 
Laboratories, Hercules, CA, USA). Equal 
amounts of protein (60 µg) from each group were 
subjected to SDS-PAGE. Separated proteins 
were blotted and transferred to a nitrocellulose 
membrane and incubated with primary antibodies 
against p-NF-κB p65 (Ser 536), p-Iκ-Bα, TNF-α, 
and Foxp3 and further incubated with 
peroxidase-labelled secondary antibody. The 
immunoreactive bands were visualised with a 
chemiluminescence system (Amersham 
Bioscience, Little Chalfont, UK). The band 
densities of the proteins analysed were 




Results are presented as mean ± standard 
deviation (SD), from three or six independent 
experiments. Data were analysed for statistical 
significance at p < 0.05 by one-way analysis of 
variance (ANOVA) followed by Duncan’s multiple 




Rutin reduced inflammatory cells in BALF 
 
Changes in total cell levels in the BALF were 
examined at 24 h after the last OVA challenge. In 
the OVA-sensitised mice, infiltration of 
inflammatory cells was observed. OVA challenge 
significantly (p < 0.05) induced influx of 
eosinophils and neurophils into BALF (Figure 1). 
Suppression of cellular infiltration was observed 
in OVA-challenged and rutin-administered mice. 
OVA-sensitised mice that were treated with rutin 
at 100 mg showed reduced eosinophil and 
neutrophil counts versus mice treated with lower 
doses of rutin. The drug control Dex also exerted 
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similar suppressive effects on cellular influx into 
BALF after OVA challenge. 
 
Rutin decreased the level of IgE in serum 
 
Th2-type cytokines exert important roles in the 
pathogenesis of allergic asthma by regulating IgE 
production. Expression and cross-linking of 
allergen-specific IgE on surfaces of mast cells 
upon specific allergen challenge initiates early 
allergic asthmatic responses. Serum levels of IgE 
specific to OVA were measured at 24 h after the 
last OVA challenge. OVA challenge resulted in a 
several-fold elevation in serum OVA-specific IgE 
levels versus the control mice (Figure 2). Rutin 
administration caused a significant decrease (p < 
0.05) in the levels of OVA-specific IgE in a dose-
dependent manner, with the 100 mg dose of rutin 
causing more marked reductions. 
 
 
Figure 1: Effect of rutin on cell accumulation in bronchoalveolar lavage fluid (BALF). Rutin significantly reduced 
cellular infiltration in the BALF. Values are presented as means ± SD, n = 6. a indicates statistical significance at 
p < 0.05 vs. the respective controls; b–f indicate significant differences (p < 0.05) between mean values as 




Figure 2: Rutin reduced ovalbumin (OVA)-specific IgE levels in serum. Values are presented as means ± SD, n = 
3. a indicates statistical significance at p < 0.05 versus the respective controls. b–f indicate significant differences 
(p < 0.05) between mean values as determined by one-way ANOVA followed by DMRT analysis 
 
Influence of rutin on Th2 cytokine levels and 
IFN-γ in BALF 
 
The influence of rutin on the expression of 
cytokines, (Th2 cytokines: IL-4, IL-5, and IL-13, 
and the Th1 cytokine, IFN-γ) in BALF was 
determined by ELISA 24 h after final OVA 
challenge. OVA challenge caused significantly 
increased (p < 0.05) BALF levels of IL-4, IL-5, 
and IL-13 versus the control group (Figure 3). 
However, the level of IFN-γ was slightly lower 
than the control group level. Rutin administration  
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Figure 3. Effects of rutin on the levels of Th2 cytokines and IFN-γ in BALF. Values are presented as means ± 
SD, n = 3; a indicates statistical significance at p < 0.05 versus the respective controls. b–f represent significant 
differences (p < 0.05) between mean values within the groups of the same cell line, as determined by one-way 
ANOVA followed by DMRT analysis 
 
caused a marked decrease in the level of Th2 
cytokines, in a dose-dependent manner, with a 
gradual increase in the level of IFN-γ in BALF. 
Rutin at 25 mg caused a reduction in levels of IL-
4, IL-5, and IL-13; the higher doses of 50 and 
100 mg caused more pronounced decreases 
with a significant increase in BALF IFN-γ levels. 
 
Rutin improved airway function and reduced 
airway hyperresponsiveness 
 
The effect of rutin on AHR in response to 
increasing concentrations of methacholine was 
determined. AHR is the excessive narrowing of 
the airways in response to various allergic stimuli 
as contractile agonists of OVA. Asthma is 
characterised by AHR. RI and Cdyn were 
measured following OVA challenge. Cdyn refers 
to lung distensibility and is defined as the change 
in volume of the lung produced by pressure 
change across the lung. RI can be defined as the 
pressure driving respiration divided by the air 
flow. In our study, the OVA-challenged mice 
developed high AHR, indicated by high RI and 
low Cdyn (Figure 4a, b). Treatment with rutin (25, 
50, or 100 mg) markedly (p < 0.05) restored 
Cdyn and reduced RI in OVA-challenged mice in 
response to methacholine in a dose-dependent 
manner. 
 
Rutin restored lung architecture 
 
Histological analysis was conducted to assess 
changes in the architecture of the lung tissue. 
H&E analysis showed that OVA challenge 
induced marked infiltration of inflammatory cells 
into the peribronchiolar and perivascular 
connective tissues versus normal lung tissue 
(Figure 5). Rutin (25, 50 or 100 mg/kg) strikingly 
suppressed infiltration of eosinophils and 
neutrophils in the lung tissues and also restored 
the normal histology. Dexamethasone treatment 
also resulted in tissue sections with almost 
negligible alterations and infiltration versus the 
control. Rutin at 100 mg showed almost no 
change in the extent of inflammatory cell 
infiltration, similar to normal histology. 
Furthermore, goblet cell hyperplasia with hyper-
secretion of mucus was observed in OVA-
challenged mice, and was almost normalised 
upon rutin treatment (Figure 6).  
 
Rutin modulated expression levels of 
proteins in the inflammatory pathway 
 
The pathogenesis of asthma development is 
associated with NF-κB activation. OVA challenge 
resulted in a robust increase in the expression 
levels of p-NF-κB p65 (Ser 536), p-I-κBα, and 
TNF-α, whereas Foxp3 expression was 
downregulated (Figure 7). However rutin 
administration caused significant decreases in 
the levels of NF-κB p65, p-I-κBα, and TNF-α, 
with s substantially elevated level of Foxp3. 
Furthermore, to assess the effects of rutin on 
Foxp3 expression at the mRNA level, RT-PCR 
was performed. Rutin at 25, 50, and 100 mg 
upregulated Foxp3 mRNA in a dose-dependent 
manner (Figure 7). The anti-inflammatory effects 
of rutin could also be due in part to the increased  
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Figure 4: Effect of rutin on airway hyperresponsiveness. Rutin markedly reduced airway resistance 




Figure 5: Rutin reduced inflammatory cell infiltration. Rutin markedly inhibited inflammatory cell recruitment into 
lung tissue. Values are presented as means ± SD, n = 3; a indicates statistical significance at p < 0.05 versus the 
respective controls; b–f represent significant differences (p < 0.05) between mean values, as determined by one-
way ANOVA followed by DMRT analysis 
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Figure 6: Rutin reduced mucus hypersecretion. Mucus hypersecretion is a characteristic of allergic asthma. Rutin 
markedly reduced mucus accumulation and hypersecretion in the bronchioles. Values are presented as means ± 
SD, n = 3. a indicates statistical significance at p < 0.05 versus the respective controls; b–f indicate significant 








Figure 7: Effects of rutin on the levels of inflammatory mediators and Foxp3. OVA-induced enhanced expression 
of NF-κB signalling pathway proteins and decreased Foxp3 expression were modulated effectively by rutin. 
Values are presented as means ± SD, n = 3; a indicates statistical significance at p < 0.05 versus the respective 
controls; b–f represent significant differences (p < 0.05) between mean values. as determined by one-way 
ANOVA followed by DMRT analysis; (L1-Control; L2-OVA; L3-25 mg Rutin + OVA; L4-50 mg Rutin + OVA; L5-
100 mg Rutin + OVA) 
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Figure 8. Rutin increased the CD4+ CD25+ Foxp3+ Treg population in BALF. CD4+ CD25+ Foxp3+ Tregs are key 
in maintaining immune homeostasis. Rutin markedly increased the CD4+ CD25+ Foxp3+ Treg cell population. 
Values are presented as means ± SD, n = 3. a indicates statistical significance at p < 0.05 versus the respective 
controls. b–f represent significant differences (p < 0.05) between mean values within groups of the same cell line, 
as determined by one-way ANOVA followed by DMRT analysis 
 
expression of Foxp3. These results suggest anti-
inflammatory effects of rutin. 
 
Influence of rutin on the CD4+ CD25+ Foxp3+ 
Treg population in BALF  
 
CD4+ CD25+ Foxp3+ Treg cells play an important 
role in the regulation of asthma pathogenesis. 
Furthermore, allergen-specific Tregs are key in 
asthma therapy. In our study, we examined the 
population of CD4+ CD25+ Foxp3+ Tregs in BALF 
of OVA-challenged mice. OVA challenge 
significantly reduced the CD4+ CD25+ Foxp3+ 
Treg cell population (Figure 8). However, rutin 
administration caused a striking increase in the 
level of CD4+ CD25+ Foxp3+ Tregs that was 
consistent with Foxp3 mRNA expression. The 
100 mg dose of rutin resulted in an increased 
population of these cells, suggesting an effect of 




Asthma is a chronic inflammatory disease of the 
lungs, characterised by infiltration of 
inflammatory cells, especially eosinophils, into 
the lungs and airways, leading to AHR, 
bronchoconstriction, and mucus production [14]. 
The prevalence of asthma is increasing rapidly 
worldwide; the disease may cause severe 
morbidity and even mortality in aggravated 
episodes. Currently, inhaled corticosteroids 
(ICSs) and bronchodilators are employed for 
asthma management for relieving 
bronchoconstriction [18]. Nevertheless, 
prolonged use of ICS at higher doses, in 
particular, has been reported to be associated 
with side effects [18] and oesophageal 
candidiasis [19]. Thus, there is a continuing need 
for the identification of new and targeted 
approaches. In our study, we investigated the 
role of rutin in exerting protective effects in an 
OVA-induced asthma model. 
 
In asthma, bronchoconstriction occurs due to 
contraction or hypertrophy of airway smooth 
muscles and inflammation, leading to decreased 
lung function [20]. AHR is a measure of such 
bronchial constriction. OVA-induced mice 
showed severely impaired Cdyn and increased 
AR. However, rutin reduced AR and improved 
lung function in response to inhaled 
methacholine. 
 
Migration of inflammatory cells, specifically 
eosinophils and lymphocytes, into the lungs is a 
key event in allergic asthma and is a major cause 
of allergic airway inflammation [21]. An increase 
in the number of eosinophils and neutrophils in 
BALF is a characteristic of asthma. In the present 
study, rutin significantly reduced the infiltration of 
inflammatory cells in BALF and lung tissues. 
 
The marked increase in levels of cytokines (IL-4, 
IL-5, IL-13) in BALF observed in our study 
following OVA sensitisation and challenge, along 
with the increased recruitment of inflammatory 
cells, is suggestive of AHR. In allergic asthma, 
the Th2 cytokines have been found to play vital 
roles in the pathogenesis of inflammation and 
also induce many features of asthma [22]. 
Effective decreases in the levels of Th2 cytokines 
with a substantial increase in IFN-γ levels 
showed the efficacy of rutin in inhibiting OVA-
induced airway inflammation and enhancing Th2 
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responses. Additionally, the balance of Th1/Th2 
cytokines is essential in regulating inflammatory 
responses. It is known that asthma and 
inflammatory responses are associated with the 
increased production of Th2 cytokines (IL-4, IL-5, 
IL-13) and reduced levels of the Th1 cytokine 
IFN-γ. Here, rutin reduced Th2 cytokine levels 
while improving IFN-γ levels, indicating a positive 
Th1/Th2 cytokine balance and anti-inflammatory 
effects. These observed decreases in Th2 
cytokines could also have caused decreased 
inflammatory cell recruitment in BALF. Because 
IL-4, IL-5, and IL-13 are associated with 
activation of eosinophils and production of IgE by 
B cells, the decrease in cytokine levels by rutin 
could have also contributed to the decreased IgE 
levels in serum, which could also have been due 
to the suppression of IgE production by rutin 
itself. 
 
Consistent with the BALF levels of cytokines and 
cellular infiltration, the histopathological analysis 
with H&E and PAS staining revealed increased 
infiltration of inflammatory cells, and the 
characteristic morphology of cells, with 
hyperproduction of mucus by goblet cells upon 
OVA challenge. Activation of allergen-induced 
Th2 cells has been reported to be associated 
with goblet cell hyperplasia and increased mucus 
secretion [23]. Rutin treatment caused the 
suppression of PAS-positive cell counts and area 
in bronchial tissues of OVA-challenged mice. 
Hypersecretion of mucus in the airway, along 
with allergic inflammation, plays a major role in 
the pathogenesis of asthma. Mucus 
accumulation in the bronchus narrows the airway 
and increases AHR. Rutin-induced inhibition of 
inflammatory cell infiltration, in BALF and in lung 
tissues, along with the decrease in cytokine 
secretion could also have contributed to 
decreased mucus production.  
 
Moreover, continued activation of NF-κB has 
been observed in allergic airway inflammation 
and is believed to be involved in airway 
remodelling in human and animal models of 
asthma [24]. NF-κB, as a vital transcription factor 
in Th2 cell differentiation [25], regulates innate 
and adaptive immune responses by causing the 
expression of various genes that are involved in 
inflammation, as well as leukocyte migration and 
activation. Nevertheless, in cells not stimulated 
by allergens, NF-κB remains sequestered in the 
cytoplasm by an inhibitor of κB (IκB) [26], 
whereas upon activation, NF-κB unit p65 
translocates from the cytoplasm to the nucleus, 
eventually leading to the synthesis and 
subsequent release of proinflammatory cytokines 
[27]. The increased expression of NF-κB p65, p-
IκB, and TNF-α suggests the activation of NF-κB 
in OVA-challenged mice, thus leading to 
expression of cytokines and inflammatory 
mediators. Rutin was found to also suppress the 
activation of NF-κB p65, IκB, and TNF-α, thus 
suppressing the NF-κB signalling pathway 
leading to inflammatory responses.  
 
Tregs, a specialised sub-population of T cells, 
exert important roles in autoimmunity and 
immune tolerance. A considerable amount of 
research has focused on naturally occurring 
CD4+ CD25+ Tregs that have been shown to be 
critically involved in preventing autoimmunity 
[28]. CD4+ CD25+ Tregs that co-express 
forkhead/winged helix transcription factor 
(Foxp3) exhibit strong anti-inflammatory roles 
and function to maintain tolerance to self-
components, either through direct contact with 
cells or by releasing anti-inflammatory cytokines 
such as IL-10 [29]. Rutin at the doses tested was 
found to markedly enhance the percentage of 
CD4+ CD25+ Foxp3+ Tregs in BALF versus the 
OVA control, with the 100 mg dose showing the 
maximum effect. Moreover, rutin treatment also 
upregulated the expression of Foxp3. 
 
The observed reductions in airway inflammation 
upon rutin treatment could be due, in part, to the 
inhibitory effects on IL-4, IL-5, and IL-13, and 
also to enhanced numbers of CD4+ CD25+ 
Foxp3+ Tregs. Foxp3 functions as a 
transcriptional repressor for various transcription 
factors, such as nuclear factor of activated T 
cells (NFAT), NF-κB, and Runx1 [30], thus 
suggesting possible multi-target molecular 
effects of rutin. Furthermore, Foxp3+ Tregs are 
known to inhibit eosinophil recruitment, mucus 
hyper-production, and Th2 cytokine release [29]. 
Thus, the enhanced Foxp3 expression and 
increased CD4+ CD25+ Foxp3+ Tregs on rutin 
treatment indicate potent anti-inflammatory 




Rutin effectively suppressed the expression of 
inflammatory mediators and regulated NF-κB 
signalling, indicating the effectiveness of rutin as 
a potential candidate for the treatment of allergic 
asthma. More clinical research is needed to 
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